Quintrio
Home

Stock overview

Sixth Street Specialty Lending, Inc.

TSLX

Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. The company partners with other companies across a variety of industries and provides creative solutions with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.

Last trade $17.23
Day change -$0.21 (-1.20%)
Day range $17.19 – $17.75
Volume 201,477
Market cap $1.67B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.67B
Price / earnings
18.75×
Price / book
1.08×
Price / sales
5.26×
EV / sales
10.72×
EV / EBITDA
35.66×

Profitability

Earnings per share
$0.93
Return on assets
2.51%
Return on equity
5.75%
Dividend yield
9.44%

Liquidity and leverage

Debt / equity
1.24×
Current ratio
—
Quick ratio
—
Cash ratio
—

Cash flow

Price / cash flow
16.14×
Price / free cash flow
16.14×
Free cash flow
$103.45M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for TSLX, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$98.2M$27.53M$87.8M$103.7M$123.18M$95.33M$118.26M$106.41M
Cost of revenue$30.09M$28.26M$31.55M$31.39M$33.65M$32.97M$37.39M$38.49M
Gross profit$68.11M-$728K$56.24M$72.31M$89.53M$62.36M$80.88M$67.92M
Selling, general and administrative$2.65M$2M$2.02M$2.23M$2.81M$2.21M$2M$2.13M
Research and development————————
Total operating expenses$25.57M$24.09M$24.89M$26.01M$29.24M$24.05M$27.56M$25.11M
Operating income$42.54M-$24.82M$31.35M$46.31M$60.29M$38.31M$53.31M$42.81M
Interest expense————————
Income before taxes$42.54M-$24.82M$31.35M$46.31M$60.29M$38.31M$53.31M$42.81M
Income taxes$2.03M$1.2M$1.39M$1.71M$1.29M$1.35M$2.32M$2.15M
Net income$40.51M-$26.03M$29.96M$44.6M$59M$36.96M$50.99M$40.66M
Net income attributable to common shareholders$40.51M-$26.03M$29.96M$44.6M$59M$36.96M$50.99M$40.66M
EBITDA$42.54M-$24.82M$31.35M$46.31M$60.29M$38.31M$53.31M$42.81M
Basic earnings per share$0.43-$0.27$0.32$0.47$0.63$0.39$0.55$0.44
Diluted earnings per share$0.43-$0.27$0.32$0.47$0.63$0.39$0.55$0.44

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches

BridgeBio Pharma announced a $1 billion preferred equity investment led by Sixth Street ($800M) and HealthCare Royalty ($133.9M). The Series A Cumulative Convertible Preferred Stock features a 7% dividend and conversion price of $137.79 per share (100%+ premium to 30-day VWAP). The capital strengthens BridgeBio's balance sheet as it prepares for potential launches of three blockbuster drugs: BBP-418 for LGMD2I/R9, encaleret for ADH1, and infigratinib for achondroplasia, while Attruby continues to grow as a multi-billion-dollar drug.

Benzinga

Figure Enters into Agreement to Acquire Kiavi, Bolstering Blockchain-Native Marketplace

Figure Technology Solutions announced a definitive agreement to acquire Kiavi, an AI-powered lending platform for residential real estate investors, for $717 million. The transaction includes a joint venture with Sixth Street to acquire Kiavi's balance sheet assets. The acquisition is expected to add $7 billion in annual first-lien volume to Figure's marketplace, advance its tokenization mission, and support Figure's 60% medium-term EBITDA margin target with accretion to earnings per share and payback in under four years.

GlobeNewswire Inc.

Enstar Announces Acquisition of AF Group

Enstar Group Limited, backed by Sixth Street Partners, has entered into a definitive agreement to acquire 100% of Accident Fund Holdings, Inc. from Blue Cross Blue Shield of Michigan for an undisclosed amount. AF Group, headquartered in Lansing, Michigan, generated $3.3 billion in consolidated gross written premium in 2025 and operates across all 50 states. The acquisition is expected to close in the second half of 2026 pending regulatory approvals, with AF Group operating as a standalone subsidiary under its existing leadership.

Investing.com

3 High Dividend BDCs With Yields Over 5%

The article discusses three Business Development Companies (BDCs) with high dividend yields over 5%, highlighting their investment strategies, financial performance, and potential attractiveness for income investors.

Benzinga

Sixth Street Completes Acquisition of Enstar

Sixth Street has completed its $5.1 billion acquisition of Enstar Group Limited, taking the company private at $338.00 per ordinary share. The transaction was approved by Enstar shareholders and will result in Enstar continuing operations as a privately held company.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily
Declared upcoming dividend $0.01 per share
Declared
Nov 3, 2026
Ex-dividend
Nov 30, 2026
Pay date
Dec 21, 2026
Ex-dividendAmount / sharePay dateType
Sep 15, 2026$0.42Sep 30, 2026recurring
Jun 15, 2026$0.42Jun 30, 2026recurring
Mar 16, 2026$0.46Mar 31, 2026recurring
Feb 27, 2026$0.01Mar 20, 2026supplemental
Dec 15, 2025$0.46Dec 31, 2025recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.